Second Xiangya Hospital of Central South University
Shenzhen People's Hospital
Peking University Cancer Hospital & Institute
Age
18–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Age 18-75 years, both sexes
Pathologically confirmed pancreatic ductal adenocarcinoma (PDAC) in treatment-naïve patients
Ability to obtain sufficient fresh tumor tissue samples for organoid establishment through surgery or biopsy
Planned to receive neoadjuvant therapy for borderline resectable disease, conversion therapy for locally advanced disease, or first-line therapy for metastatic disease, using single-agent or combination chemotherapy
At least one measurable lesion per RECIST 1.1 criteria
ECOG performance status 0-2
Life expectancy ≥3 months
Adequate organ and bone marrow function: hemoglobin ≥9.0 g/dL; absolute neutrophil count ≥1.5×10⁹/L; platelet count ≥100×10⁹/L; total bilirubin ≤1.5×ULN (or ≤3×ULN with biliary obstruction); ALT/AST ≤2.5×ULN (or ≤5×ULN with biliary obstruction); serum creatinine ≤1.5×ULN or CrCl \>60 mL/min
Willing to sign informed consent, good compliance, and able to comply with follow-up
You may not be if
Sample quantity, quality, or preservation does not meet requirements
Expected transport time \>24 hours (including samples stored overnight before delivery)
Organoid culture failure or testing quality control failure
Inability to tolerate chemotherapy regimens
Severe comorbidities, uncontrolled conditions, or active infections
Pregnancy or breastfeeding
History of severe autoimmune diseases
Any unstable condition that may compromise patient safety or compliance
Deemed unsuitable for inclusion by the investigator
Clareo Health | Patient-Derived Organoid-on-a-Chip Model for Personalized Prediction of Chemotherapy Efficacy in Pancreatic Cancer
